Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nandini Channabasappa

Pediatric Gastroenterology Dallas, TX Medical Doctor

NPI 1477765113 CMS profile 111889

1935 Medical District Dr, Dallas, TX 75235

Open in the dashboard

General payments

$11,645

184 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nandini Channabasappa of Dallas, TX is reported in the CMS Open Payments database as having received $11,645 across 184 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Pediatric Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $572 22
2024 General $756 29
2023 General $539 27
2022 General $902 24
2021 General $495 23
2020 General $4,745 24
2019 General $3,637 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nandini Channabasappa
  • Pediatric Gastroenterology median
  • Middle half of Pediatric Gastroenterology
  • National median

In program year 2025, general payments to Nandini Channabasappa were reported at $572. Among 1,132 Pediatric Gastroenterology profiles paid that year, the median was $194 and the middle half received between $81 and $540.

Show as a table
Year Nandini Channabasappa Pediatric Gastroenterology median Middle half National median
2019 $3,637 $131 $41–$311 $163
2020 $4,745 $79 $23–$223 $114
2021 $495 $104 $32–$321 $132
2022 $902 $125 $37–$331 $149
2023 $539 $169 $55–$440 $160
2024 $756 $196 $73–$563 $164
2025 $572 $194 $81–$540 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $5,084 43 payments
  2. Alcresta Therapeutics, Inc. $3,184 8 payments
  3. AbbVie, Inc. $948 36 payments
  4. QOL Medical, LLC $655 26 payments
  5. Genzyme Corporation $353 11 payments
  6. Regeneron Healthcare Solutions, Inc. $350 11 payments
  7. Janssen Biotech, Inc. $255 15 payments
  8. Mirum Pharmaceuticals, Inc. $174 9 payments
  9. Albireo Pharma, Inc. $143 2 payments
  10. Alexion Pharmaceuticals, Inc. $87 4 payments
  11. Other $411 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $6,891 2 payments
  2. Food and Beverage $4,142 178 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $590 3 payments
  4. Education $22 1 payment
Products named General payments · program years 2019–2025
  1. RELIZORB $3,040 2 payments
  2. GATTEX $960 34 payments
  3. HUMIRA $817 30 payments
  4. Sucraid $591 23 payments
  5. DUPIXENT Immunology $353 11 payments
  6. DUPIXENT Inflammation And Immunology $323 10 payments
  7. REMICADE $222 13 payments
  8. Bylvay $200 5 payments
  9. EOHILIA $160 8 payments
  10. Livmarli $156 8 payments
  11. Other $1,064 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

184 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Gastroenterology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record